Quantcast

Latest Allergan Inc. Stories

2014-07-24 08:33:41

LAVAL, Quebec, July 24, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. ("Valeant") (NYSE:VRX) (TSX:VRX) announced today that it has filed a detailed complaint with the Autorite des marches financiers ("AMF") regarding Allergan, Inc.'s (NYSE: AGN) apparent attempts to mislead investors and to negatively influence the market price of Valeant's common shares by continuing to make false and misleading statements regarding Valeant's business despite Valeant's public statements...

2014-07-18 23:03:28

ReportsnReports.com adds “United States Bariatric Surgery Devices Market Outlook to 2020” to its store. The objective is to provide information that represents the most up-to-date data of the industry possible. Dallas, TX (PRWEB) July 18, 2014 "United States Bariatric Surgery Devices Market Outlook to 2020" provides key market data on the United States Bariatric Surgery Devices market. The report provides value in millions of US dollars, volume (in units), and average prices...

2014-07-14 08:26:41

LAVAL, Quebec, July 14, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) today announced it has filed a premerger notification under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR) with the U.S. Federal Trade Commission (FTC) relating to the proposed acquisition of Allergan, Inc. (NYSE: AGN). About Valeant Pharmaceuticals International, Inc. Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty...

2014-06-25 08:30:57

LAVAL, Quebec, June 25, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. ("Valeant") (NYSE: VRX) (TSX: VRX) today announced the filing of a preliminary proxy statement for a special meeting of shareholders, at which Valeant shareholders will consider and vote upon, among other things, a proposal to approve the issuance of Valeant common shares in connection with an acquisition of Allergan, Inc. ("Allergan") (NYSE: AGN). Valeant commenced an exchange offer for the common...

2014-06-24 08:29:55

DUBLIN, June 24, 2014 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/f9mqvw/global_uveitis) has announced the addition of the "Global Uveitis Market 2014-2018" report to their offering. http://photos.prnewswire.com/prnh/20130307/600769 Currently, the current competition in the Global Uveitis market is weak and the available treatment options have only been moderately successful in meeting market demand. The current market is served in the main by three...

2014-06-23 08:28:35

LAVAL, Quebec, June 23, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that, as promised, it has posted fact-based answers to refute misleading assertions made by Allergan, Inc. (NYSE: AGN) in its June 10(th) presentation. Valeant's presentation is posted at http://valeant.com/about/valeant-allergan. Valeant intends to provide future updates to this document as appropriate. About Valeant Pharmaceuticals International, Inc. Valeant...

2014-06-18 12:32:37

LAVAL, Quebec, June 18, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. ("Valeant") (NYSE: VRX) (TSX: VRX) today announced that it has commenced an exchange offer for the common stock of Allergan, Inc. ("Allergan") (NYSE: AGN), taking its May 30(th) proposal directly to Allergan stockholders. Under the terms of the offer, Allergan stockholders would be able to elect to exchange each of their Allergan shares for $72.00 in cash and 0.83 Valeant common shares, or an amount of...

2014-06-13 12:25:00

LAVAL, Quebec, June 13, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that it will conduct a fact-based presentation to refute recent misleading assertions made by Allergan, Inc. (NYSE: AGN) and others, as well as answer additional investor questions, on June 17, 2014. Conference Call and Webcast Information The Company will host a conference call and a live Internet webcast along with a slide presentation at 8:00 a.m. ET (5:00 a.m....

2014-05-30 16:24:44

- Cash of $72.00 per share and 0.83 Shares of Valeant stock LAVAL, Quebec, May 30, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. ("Valeant") (NYSE: VRX) (TSX: VRX) today announced that it is making an offer for Allergan, Inc. (NYSE: AGN) under which each Allergan share would be exchanged for $72.00 in cash and 0.83 shares of Valeant common stock, based on the fully diluted number of Allergan shares outstanding. This offer is subject to prompt good faith negotiation of a...

2014-05-28 08:30:03

LAVAL, Quebec, May 28, 2014 /PRNewswire/ -- -- Increases Cash Consideration by $10.00 per share to $58.30, approximately 21 Percent Increase -- Maintains 0.83 of a Valeant share -- Adds Contingent Value Right for DARPin of up to $25.00 per Share in Value -- Valeant Commits to Invest up to $400 Million in DARPin and Retain Current Allergan Employees Responsible for Development -- Represents 40 Percent of DARPin Net Sales after...


Word of the Day
holluschickie
  • A 'bachelor seal'; a young male seal which is prevented from mating by its herd's older males (mated bulls defending their territory).
This comes from the Russian word for 'bachelors.'
Related